Call for Proposals: Advances in the Conduct of Randomized Controlled Trials

The Accelerating Clinical Trials / Accélérer les Essais Cliniques (ACT/AEC) Consortium is pleased to announce a call for proposals entitled: “Advances in the Conduct of Randomized Controlled Trials.”

This ACT request is designed for 2 separate streams of proposals:
  1. Stream 1: Encourage randomized trials that use non-traditional and efficient designs and approaches. The trial methods should still be robust (i.e., minimize the risk of bias)
  2. Stream 2: Generate high-quality evidence on methods to improve the conduct of trials
CDTRP Support Request

To apply, your application must be endorsed by one of the ACT Networks, such as CDTRP. To seek CDTRP endorsement, please submit a support request by MAY 29, 2023.

Deadline: May 29, 2023
About the Accelerating Clinical Trials/Accélérer les Essais Cliniques Consortium

On January 19th, the Canadian Institutes for Health Research (CIHR) formally announced that the Accelerating Clinical Trials/Accélérer les Essais Cliniques (ACT/AEC) Canada Consortium was the successful applicant for the federal grant for a 3-year term.

The ACT/AEC Canada Consortium consists of hundreds of investigators, patient-partners, healthcare professionals, government, and the biotechnology industry, as well as highly qualified personnel (e.g., study coordinators, biostatisticians) at 28 research networks and 11 clinical trial units located across the country, to address operational bottlenecks to conducting clinical trials in Canada. The ACT/AEC Consortium spans from Nova Scotia to British Columbia and Nunavut.